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Objective: The aim of our study was to evaluate the individual contribution of parity when incorporated
as another parameter into the four risk of malignancy indices (RMI 1e4) to differentiate noninvasive
benign lesions from invasive malignant ovarian lesions.
Materials and methods: After calculating RMI 1e4 for each patient included in this study, the resulting
RMI scores were further multiplied by the parity score (P) of each patient to calculate the RMI parity
(RMIP) score.
Results: A cutoff value of 300 for RMIP 1 yielded 95.0% speciﬁcity, 97.4% negative predictive value (NPV),
88.5% sensitivity, and 79.3% positive predictive value (PPV) and performed better than RMI 1 in the
preoperative diagnosis of invasive malignant lesions. RMIP 2 with a cutoff value of 400 yielded 95.0%
speciﬁcity, 97.4% NPV, 88.5% sensitivity, and 79.3% PPV, and it also performed better than RMI 2. A cutoff
value of 400 for RMIP 3 provided 97.5% speciﬁcity, 97.5% NPV, 88.5% sensitivity, and 88.5% PPV and
performed better than RMI 3. However, a cutoff value of 400 for RMIP 4 provided 90.0% speciﬁcity, 97.3%
NPV, 88.5% sensitivity, and 65.7% PPV but did not perform better than RMI 4 in the preoperative diag-
nosis of invasive malignant lesions.
Conclusion: RMIP 1e3 scales were more reliable tools for the preoperative diagnosis of invasive adnexal
masses compared with the traditional RMI 1e3 scales.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ovarian cancer (OC) ranks second among gynecological malig-
nancies. Symptoms related to OC are typically nonspeciﬁc, and their
association is often not recognized until the disease has reached an
advanced stage. Recognizing OC at an early stage is very important
[1], because the extent of disease at diagnosis is the primary
determinant of survival [2]. Optimal debulking surgery performed
in patients with OC is another signiﬁcant prognostic factor [3], and
accurate surgical staging of early-stage OC patients has great sig-
niﬁcance, permitting accurate estimation of the true extent of
disease while detecting occult disease, and providing patients withand Gynaecology, Faculty of
urkey.
uzcan).
bstetrics & Gynecology. Publishedappropriate information about prognosis and adjuvant treatment
[4].
Ultrasonography (USG) and the measurement of serum cancer
antigen-125 (CA-125) levels are commonly performed preopera-
tively to predict the histopathological nature of adnexal masses [5].
CA-125 levels >30 U/mL suggest a risk for malignancy [6], although
patient age and menopausal status are also important factors in the
preoperative evaluation of adnexal masses [7]. In 1990, Jacobs et al
[6] introduced the Risk of Malignancy Index (RMI 1), which is based
on serum CA-125 levels, menopausal status, and USG ﬁndings.
Using the same parameters, Tingulstad et al [8,9] propounded RMI
2 and subsequently RMI 3. More recently, Yamamoto et al [10]
suggested the use of RMI 4 for preoperative evaluation of malig-
nant adnexal masses by incorporating the size of the adnexal mass
on USG as a variable in the risk calculation.
The relationship between parity and epithelial ovarian cancer
(EOC) has been demonstrated in numerous studies: the risk of OC
decreases with increasing parity [11,12]. The birth of the ﬁrst child,by Elsevier Taiwan LLC. All rights reserved.
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clines further with each full-term pregnancy [13]. However, Schüler
et al [14] evaluated the relationship between OC and several
reproductive factors, including parity, and their results were
inconclusive. None of the indices that have been used previously to
determine the malignancy risk of adnexal masses have evaluated
the individual contribution of a healthy term pregnancy on the risk
of malignancy [6,8e10].
The aim of our study was to evaluate the individual contribution
of parity, when incorporated as another parameter into the four
malignancy indices, in the differentiation of noninvasive benign
lesions from invasive malignant ovarian lesions.Materials and methods
This study included patients with a prediagnosis of an adnexal
mass who underwent surgery in the Department of Obstetrics and
Gynecology at Düzce University Faculty of Medicine (Düzce,
Turkey) and in Ankara Zekai Tahir Burak Women's Health Educa-
tion and Research Hospital (Ankara, Turkey) between November
2009 and May 2013. A total of 153 nonpregnant Caucasian women
>18 years of age with no history of malignancy were evaluated. The
data were retrieved retrospectively by reviewing the patients'
medical charts. All patients provided written consent prior to the
surgery. The patients were evaluated by USG 2 weeks before sur-
gery and underwent an excision of the adnexal mass using surgical
staging, performed in accordance with the guidelines of the Inter-
national Federation of Gynecology and Obstetrics, if the diagnosis
from the frozen section examinationwas malignant [15]. All benign
lesions, tumors of borderlinemalignancy, and any other lesions that
did not invade the epithelial basement membrane were classiﬁed
as benign adnexal masses [16]. Invasive malignant neoplasms and
metastatic masses were considered malignant adnexal mass. An
invasive malignant mass was detected in 24 patients (15.8%), and
noninvasive benign lesions were found in 129 patients (84.2%). The
histopathological diagnoses of the adnexal masses are presented in
Table 1.
Postmenopausal patients were deﬁned as patients with an
absence of menstrual ﬂow for 1 year. The parity score was deﬁnedTable 1
Histopathological diagnoses of adnexal masses.
Noninvasive benign
lesions
n (%) Invasive malignant
lesions
n (%)
 Brenner tumor 1 (0.7%)  Clear cell carcinoma 1 (0.7%)
 Borderline serous
tumor
7 (4.9%)  Endometrioid-type
carcinoma
3 (2.0%)
 Borderline mucinous
tumor
1 (0.7%)  Malignant mesenchymal
tumour
1 (0.7%)
 Corpus hemorrhagicum
cyst
6 (3.9%)  Malignant mucinous
carcinoma
3 (2.0%)
 Corpus luteum cyst 3 (2.0%)  Serous carcinoma 16 (10.4%)
 Endometrioma 24 (15.6%)
 Fibroma 1 (0.7%)
 Follicular cyst 6 (4.2%)
 Mature cystic teratoma 21 (13.7%)
 Mucinous cyst 4 (2.8%)
 Mucinous cystadenoma 5 (3.5%)
 Uterine ﬁbroids 4 (2.8%)
 Paraovarian cyst 2 (1.4%)
 Paratubal cyst 7 (4.9%)
 Serous cyst 12 (7.8%)
 Serous cystadenoma 14 (9.2%)
 Serous papillary
cystadenoma
4 (2.8%)
 Struma ovarii 1 (0.7%)
 Thecoma 1 (0.7%)
 Tuba-ovarian abscess 5 (3.5%)as the number of pregnancies that resulted in full-term births. CA-
125 levels were determined using an electrochemiluminescence
immunoassay and expressed in IU/mL. The upper limit of the
normal range for the serum CA-125 level was set at 30 IU/mL.
Analysis of RMI
The RMI score was calculated by multiplying together the
transvaginal USG results (U), menopausal status (M), and preop-
erative CA-125 levels (IU/mL). For this calculation, different co-
efﬁcients were used for RMI 1, 2, and 3 [6,8,9]. For RMI 4, the
calculation also included mass size (S) as one of the variables
measured by transvaginal USG [10] (Table 2). The total USG scores
(U) were determined based on the ﬁndings on transvaginal USG
that were suspicious for malignancy. These ﬁndings included the
appearance of multilocular cystic lesions, solid area, bilaterality,
ascites, and presence of intra-abdominal metastasis.
Analysis of the RMI parity score
After calculating RMI 1e4 for each patient, the resultant RMI
scores were further multiplied by the parity score (P) of the indi-
vidual patient to calculate RMI parity (RMIP) 1e4. This P score was
deﬁned as 3 for nulliparous women, 2 for womenwith a parity of 1,
and 1 for women with parity 2.
Statistical analysis
SPSS 21.0 was used for the statistical analyses (IBM Corp.,
Armonk, NY, USA). Means, standard deviations, minimum and
maximumvalues, medians, proportions, and frequencies were used
for the descriptive statistics. The level of impact was measured
using receiver operating curve (ROC) analysis. Kappa (k) analysis
was used to assess agreement. A p value <0.05 was considered
statistically signiﬁcant.
Results
The mean age of the study participants was 46.05 ± 11.39 years,
and 54 patients (35.3%) were postmenopausal. The mean parity of
the patients was 2.46 ± 1.62, and the mean preoperative CA-125
level was 75.82 ± 112.53 IU/mL. The general characteristics of the
patients are shown in Table 3.
We evaluated the power of RMIP 1e4 to differentiate noninva-
sive benign lesions from malignant invasive adnexal masses. RMIP
1 signiﬁcantly differentiated invasive benign lesions from malig-
nant adnexal masses [area under the curve (AUC) ¼ 0.96; 95%
conﬁdence interval (CI), 0.92e1.00; p ¼ 0.000). RMIP 2 successfully
differentiated benign and malignant adnexal masses (AUC ¼ 0.96;
95% CI, 0.91e1.00; p ¼ 0.000). RMIP 3 showed a signiﬁcant distri-
bution for differentiation of benign from malignant lesions
(AUC ¼ 0.96; 95% CI, 0.91e1.00; p ¼ 0.000). RMIP 4 was also found
to be reliable for differentiating benign from malignant lesions
(AUC ¼ 0.97; 95% CI, 0.93e1.00; p ¼ 0.000) (Graph).
Further analysis determined that the k value for RMI 1was 0.691
(p ¼ 0.000). A cutoff value of 200 [6] for RMI 1 yielded 90.0%
speciﬁcity, 97.3% negative predictive value (NPV), 88.5% sensitivity,
and 65.7% positive predictive value (PPV) (Table 4). When evalu-
ating an adnexal mass preoperatively based on RMIP 1, a cutoff
value of 300 (if300 was noninvasive and >300 invasive) provided
good discrimination that correlated signiﬁcantly with the histo-
pathological results (k ¼ 0.759, p ¼ 0.000). A cutoff value of 300
provided 95.0% interobserver agreement, yielding 95.0% speciﬁcity,
97.4% NPV, 88.5% sensitivity, and 79.3% PPV (Table 5). Our ﬁndings
Graph. The power of RMIP 1e4 to differentiate noninvasive from invasive lesions.
RMIP ¼ risk of malignancy index parity.
Table 2
Coefﬁcients in RMI indexes.
Parameter RMI 1 RMI 2 RMI 3 RMI 4
Jacobs
et al [6]
Tingulstad
et al [8]
Tingulstad
et al [9]
Yamamoto
et al [10]
USG score (U)
No feature 0 1 1 1
1 feature 1 1 1 1
2 features 3 4 3 4
Menopausal score (M)
Premenopausal state 1 1 1 1
Postmenopausal state 3 4 3 4
CA-125 (U/mL) d d d d
Size of mass (S)
<7 cm d d d 1
7 cm d d d 2
CA-125 ¼ cancer antigen-125; RMI ¼ risk of malignancy index;
USG ¼ ultrasonography.
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operative diagnosis of invasive malignant lesions.
The k value for RMI 2was 0.599 (p¼ 0.000). A cutoff value of 200
[8] yielded 85.0% speciﬁcity, 97.1% NPV, 88.5% sensitivity, and 56.1%
PPV (Table 4). When evaluating an adnexal mass preoperatively
based on RMIP 2, a cutoff value of 400 (if400was noninvasive and
>400 invasive) provided good discrimination that correlated
signiﬁcantly with the histopathological results (k ¼ 0.799,
p ¼ 0.000). A cutoff value of 400 provided 93.8% interobserver
agreement, yielding 95.0% speciﬁcity, 97.4% NPV, 88.5% sensitivity,
and 79.3% PPV (Table 5). Our ﬁndings determined that RMIP 2
performed better than RMI 2.
The k value for RMI 3was 0.643 (p¼ 0.000). A cutoff value of 200
[9] yielded 87.5% speciﬁcity, 97.2% NPV, 88.3% sensitivity, and 60.5%
PPV (Table 4). In the preoperative evaluation of an adnexal mass
based on RMIP 3, a cutoff value of 400 (if400was noninvasive and
>400 invasive) provided good discrimination that correlated
signiﬁcantly with the histopathological results (k ¼ 0.860,
p ¼ 0.000). A cutoff value of 400 provided 95.9% interobserver
agreement, yielding 97.5% speciﬁcity, 97.5% NPV, 88.5% sensitivity,
and 88.5% PPV (Table 5). In our study, RMIP 3 showed a higher
performance than RMI 3 in the preoperative diagnosis of invasive
malignant lesions.
The k value for RMI 4was 0.761 (p¼ 0.000). A cutoff value of 450
[10] yielded 93.3% speciﬁcity, 97.4% NPV, 88.3% sensitivity, and
74.2% PPV (Table 4). In the preoperative evaluation of an adnexal
mass based on RMIP 4, a cutoff value of 400 (if 400 was nonin-
vasive and >400 was invasive) provided good discrimination that
correlated signiﬁcantly with the histopathological results
(k ¼ 0.691, p ¼ 0.000). A cutoff value of 400 provided 89.7% inter-
observer agreement, yielding 90.0% speciﬁcity, 97.3% NPV, 88.5%
sensitivity, and 65.7% PPV (Table 5). Thus, RMI 4 was more reliable
than RMIP 4.Table 3
General features of the patients.
n (%) Mean ± SD
Age (y) 153 (100%) 46.05 ± 11.39
Menopause 54 (35.3%)
Gravida 153 (100%) 2.99 ± 1.96
Parity 153 (100%) 2.46 ± 1.62
CA-125 (IU/mL) 153 (100%) 75.82 ± 112.53
Measured size on USG (mm) 153 (100%) 84.49 ± 39.20
CA-125 ¼ cancer antigen-125; SD ¼ standard deviation; USG ¼ ultrasonography.Discussion
The RMI is used commonly in practice to differentiate benign
from malignant adnexal masses. It is advantageous because it is a
low-cost, objective, and readily applicable method. When the RMI
was ﬁrst introduced by Jacobs et al [6], they reported 85% sensi-
tivity and 97% speciﬁcity using a cutoff value of 200 for RMI 1 [6]. In
a study by Tingulstad et al [8], a cutoff value of 200 yielded 80%
sensitivity, 92% speciﬁcity, and 83% PPV in the diagnosis of malig-
nancy. Tingulstad et al [8] subsequently proposed RMI 3, which
incorporated the USG score and menopause score into RMI 2, and
reported 71% sensitivity and 92% speciﬁcity [9]. The most extensive
modiﬁcation in the traditional RMI 1e3 scales was made by
Yamamoto et al [10], who proposed RMI 4, based on the assumption
that the size of the adnexal masses could be associated with a
higher risk of malignancy. A cutoff value of 450 for RMI 4 yielded
86.8% sensitivity, 91.0% speciﬁcity, 63.5% PPV, 97.5% NPV, and 90.4%
accuracy in the preoperative diagnosis of malignant adnexal lesions
[10]. Studies in subsequent years have also suggested that RMI 1e4
could be used reliably in the preoperative diagnosis of malignant
adnexal masses [17,18]. This was supported by our study, which
determined that RMI 1e4 was successful in differentiating benign
from malignant invasive adnexal masses (Table 4).
After the progressmade by Yamamoto et al [10], there have been
no recent reports attempting to differentiate malignant adnexal
lesions in the preoperative period more reliably and to improve the
diagnostic efﬁciency of RMI. Instead, more complex and expensive
tests have been introduced for the diagnosis of OC, such as human
epididymis protein 4 (HE4) or the international ovarian tumor
analysis (IOTA) logistic regression models [19]. In our study, we
evaluated the inﬂuence of incorporating parity into RMI as a
determinant of lifelong estrogen exposure and the total number of
ovulations. Uninterrupted ovulation and excessive exposure to
gonadotropin release are thought to play a major role in the
development of OC [20]. Oral contraceptives inhibit ovulation, and
a comprehensive report in 2013 determined that oral contracep-
tives were effective in the prevention of OC, but the duration of
their use is the most important determinant of this [21]. Pregnancy
reduces the risk of EOC by suspending ovulation and inhibiting the
synthesis of gonadotropins, an effect similar to that of oral con-
traceptives. Moreover, because pregnancy raises estrogen and
progesterone levels [14], the increased progesterone levels may
prevent OC by inhibiting the proliferation of the ovarian epithe-
lium, thereby accelerating cellular differentiation and promoting
Table 4
Evaluation of the reliability of RMI 1e4 in diagnosing malignant adnexal lesions.
Benign
(n ¼ 129)
Malignant
(n ¼ 24)
Speciﬁcity (%) NPV (%) Sensitivity (%) PPV (%) Kappa p
RMI 1 200 117 3 90.0 97.3 88.5 65.7 0.691 <0.001
>200 12 21
RMI 2 200 111 3 85.0 97.1 88.5 56.1 0.599 <0.001
>200 18 21
RMI 3 200 114 3 87.5 97.2 88.5 60.5 0.643 <0.001
>200 15 21
RMI 4 450 121 3 93.3 97.4 88.5 74.2 0.761 <0.001
>450 8 21
NPV ¼ negative predictive value; PPV ¼ positive predictive value; RMI ¼ risk of malignancy index.
Table 5
Evaluation of the reliability of RMIP 1e4 in diagnosing invasive malignant adnexal lesions.
Benign
(n ¼ 129)
Malignant (n ¼ 24) Speciﬁcity (%) NPV (%) Sensitivity (%) PPV (%) Kappa p
RMIP 1 300 123 3 95.0 97.4 88.5 79.3 0.799 <0.001
>300 6 21
RMIP 2 400 123 3 95.0 97.4 88.5 79.3 0.799 <0.001
>400 6 21
RMIP 3 400 126 3 97.5 97.5 88.5 88.5 0.860 <0.001
>400 3 21
RMIP 4 400 115 3 90.0 97.3 88.5 65.7 0.691 <0.001
>400 12 21
NPV ¼ negative predictive value; PPV ¼ positive predictive value; RMIP ¼ risk of malignancy index parity.
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terrupted ovulation decreases.
Parity is a strong protective factor, particularly against EOC, and
the effect is further intensiﬁed by increasing the number of births
[24]. Pasalich et al [25] showed a 60% lower risk of EOC in women
with parity3 as compared with womenwith parity <1. The risk of
OC is reduced by 80% in womenwith parity >5 [26], and increasing
parity also protects women against the development of borderline
tumors [27].
Our results describing the efﬁcacy of RMI 1e4 are in agreement
with previous case-control studies [6,8e10]. We assumed that
parity could inﬂuence the risk of malignancy in a given adnexal
lesion and, in contrast to other studies, determined that RMIP 1, 2,
and 3 performed well in differentiating invasive malignant lesions
with cutoff values of 300, 400, and 400, respectively. The concor-
dance between preoperative diagnosis and histopathological
diagnosis was higher for RMIP 1e3 compared with RMI 1e3 in our
population. In addition, the speciﬁcities of RMIP 1e3 in diagnosing
invasive malignant ovarian lesions were higher than those of RMI
1e3, with higher PPV. Furthermore, RMIP 4 offered signiﬁcant ad-
vantages over RMI 4.
The diagnostic performances of the RMIP 1e3 scales in our
study were superior to those of the RMI 1e3 scales reported in
previous studies [6,8e10,16,18]. Thus, the use of RMIP 1e3 scales
may result in greater diagnostic accuracy for malignancy in OC
patients. Likewise, we showed that the number of patients under-
going an inadvertent operation despite the presence of a benign
adnexal mass would be lower using RMIP 1e3. RMIP 1 with a cutoff
value of 300 showed similar efﬁciency as RMIP 2 with a cutoff value
of 400. RMIP 3 with a cutoff value of 400 offered the highest per-
formance in differentiating benign frommalignant adnexal masses
in our study. Yamamoto et al [10] claimed that RMI 4 was more
reliable than RMI 1e3, and that RMI 4 at a cutoff level of 450 yielded
a sensitivity of 86.8%, speciﬁcity of 91.0%, and PPV of 63.5%. In our
study, RMIP 3 at a cutoff level of 400 showed a sensitivity of 88.5%,
speciﬁcity of 97.5%, and PPV of 88.5%.
The RMIP 1e3 scales are more reliable tools in the preoperative
diagnosis of invasive adnexal masses compared with the traditionalRMI 1e3 scales. The traditional RMI 4 scale was thought to be the
most accurate index; however, our study demonstrated that RMIP 3
is more accurate in differentiating benign from malignant invasive
adnexal masses, compared with the RMI 4 scale. Comprehensive
studies performed in different populations are warranted to
determine the use of these new indices as reliable alternatives to
the traditional four malignancy risk indices.
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